1 August 2025
Ropes & Gray Advises Viridian Therapeutics in Japan Licensing Deal with Kissei Pharmaceutical for Thyroid Eye Disease Treatments
Advising firms
Deal team
4 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Hannah England Lead | Ropes & Gray | Partner | life sciences licensing | Not stated |
| Nicole Rohr | Ropes & Gray | Associate | life sciences licensing | Not stated |
| Ryan Kramer | Ropes & Gray | Associate | life sciences licensing | Not stated |
| David Saltzman | Ropes & Gray | Partner | tax | Not stated |
1 more lawyer on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 70m ($70 million)
- What the figure measures
- Total transaction value
- Client
- Viridian TherapeuticsIssuer
- Counterparties
- Kissei Pharmaceutical (Other)